Answers are grounded in this paper and cite their sources.
Dear Editor, We report a patient who developed severe circulatory failure due to Autoimmune/inflammatory Syndrome Induced by Adjuvants (ASIA) and showed prominent and rapid improvement, followed by complete recovery, after adjuvant-silicone breast implant (SBI) removal. A 36-year-old lady with Fontan circulation presented to our clinic with symptoms of circulatory failure. Born with tricuspid atresia, ventricular septal defect and pulmonary valve stenosis, she underwent a Fontan correction at 4 years of age. She was regularly followed. Recently she had been admitted to another hospital for progressive dyspnoea, sudden weight gain (7 kg in 1 week), peripheral oedema and ascites. She had elevated liver function tests [aspartate transaminase (SGOT): 34 U/l, alanine transaminase (SGPT): 34 U/l, gamma-glutamyl transferase (GGT): 80 U/l, alkaline phosphatase (ALP): 266 U/l], B-type natriuretic peptide (NT-proBNP) (1982 pg/ml) and CRP (137 mg/dl). Echocardiography showed good left ventricular systolic function with mild mitral regurgitation (Supplementary Videos 1 and 2, available at Rheumatology online). Abdominal US described hepatosplenomegaly, signs of advanced hepatic fibrosis and large ascites. CT angiography excluded any obstruction in the Fontan system and confirmed advanced hepatic disease (Fig. 1). She responded well to i.v. diuretics, and lost over 8 l of oedema. Fontan failure and severe Fontan-associated liver disease were diagnosed, and she was recommended urgent cardiac transplantation, potentially combined with liver transplantation dependent on her further results. (A, B) Abdominal US study showed an enlarged liver with nodular margins, inhomogeneous parenchymal structure, dilated portal veins with hepatofugal flow pattern, recanalized umbilical vein and large ascites. (C, D) CT angiography excluded any obstruction in the Fontan system and confirmed advanced hepatic disease The patient came to our clinic for a second opinion. At presentation, she had already regained over 9 kg since her discharge 10 days ago, despite being on 250 mg furosemide daily. Thorough history taking revealed that her sudden symptoms developed a few weeks after she got SBI implanted. With suspicion of an immunological reaction, an autoimmune panel was taken. Autoantibodies (ANA, anti-Scl70, anti-Jo-1, anti-SSA/Ro, anti-SSB/La, anti-Sm, anti-dsDNA and RF) came back negative, but she displayed markedly elevated IL-6 levels of 101 pg/ml (norm: <7 pg/ml). The patient was informed about a potential interaction between the SBI and her deterioration, and decided to get the implants removed. Bilateral implant removal with capsulectomy was performed 9 weeks after the implantation. The prostheses were intact, without signs of macroscopic rupture. Her symptoms improved within days. Over the following weeks, she completely lost her ascites, her liver status improved on imaging and her cardiological status normalized. Immunosuppressive therapy was not applied. Seventeen months later, she is in a stable cardiac condition on 20 mg furosemide once a week. Her laboratory values returned to near normal values, representative of a compensated Fontan circulation (NT-proBNP: 384 ng/l, SGOT: 31 U/l, SGPT: 29 U/l, GGT: 61 U/l, CRP: 19 mg/l.) ASIA is an immune-mediated condition with autoimmune and inflammatory symptoms that occur as a result of exposure to environmental immune stimulatory factors in genetically susceptible individuals. Adjuvants entering the human body as external agents can trigger a specific immune reaction. Clinical symptoms induced by SBIs are of particular importance [1]. Since the first description of the syndrome in 2011, the number of clinical manifestations linked to the disease is constantly increasing [2]. The typical ASIA-related symptoms include arthralgias, myalgias, chronic fatigue, sicca symptoms, sleep disturbances, pyrexia and cognitive impairment [1]. Silicone implant is associated with an increased risk of developing local and systemic inflammatory and autoimmune reactions. To date, we have conflicting evidence regarding the histocompatibility between the SBI and its environment, as well as its exact pathomechanism on immune homeostasis. Despite this, the in vitro experimental models performed on different cell types open the possibility of understanding the immune pathomechanism involved in the development of capsule contracture around SBI. As a first step in the process, monocyte-differentiated macrophages can mediate silicone-induced adverse reactions, such as foreign body reaction and fibrous encapsulation. As a result of silicone phagocytosis by macrophages, the secretion of pro-inflammatory and pro-fibrotic cytokines such as TNF-α and IFN-γ, IL-6 is significantly increased. IL-6, as a key cytokine, induces the development of Th17 cells mainly by producing IL-17, IL-6, IL-8 and IFN-γ, and participates in the transformation of fibroblasts into myofibroblasts. The resulting chronic inflammation is accompanied by the differentiation of myofibroblasts, mainly through the mediation of the profibrotic cytokine TGF-β [3]. In addition, the capsules surrounding SBIs contain Th1/Th17 inflammatory cells that release large amounts of IL-6, IL-8, IL-17 and IFN-γ, as well as altered function of regulatory T cells [4]. All these processes can play a role in the development of local and systemic inflammatory and autoimmune processes in the case of SBI implantation. Cardiovascular complications are less well known in ASIA syndrome—so far orthostatic intolerance, postural tachycardia syndrome and pericardial effusion have been described [5]. Severe, life-threatening manifestations of ASIA may occur occasionally after exposure to an adjuvant, however severe circulatory failure has not been reported so far [6]. In the Fontan circulation, the systemic venous return is connected to the pulmonary arteries without a pre-pulmonary pump. The residual postcapillary energy is not allowed to run off to the systemic venous atrium, but rather is used to push blood through the lungs. The Fontan circulation tolerates only a small range of ventricular filling pressures; any increase in filling pressure, such as atrioventricular valve regurgitation, or elevated end-diastolic pressure in the single ventricle, will result in more systemic venous congestion and less cardiac output. Heart failure (HF), including acute decompensations, has been demonstrated to be driven at least in part by inflammatory pathways. There is evidence that inflammation in acute HF may contribute to changes in vascular resistance, fluid redistribution, pulmonary congestion, diastolic dysfunction and systemic hypoperfusion [7–9]. IL-6 is a central signalling cytokine that controls both inflammatory and immune responses. Increased IL-6 levels are associated with an increased risk for developing incident HF, predominantly HF with preserved ejection fraction [10, 11]. IL-6 can provoke myocardial dysfunction through increasing cardiomyocyte stiffness by reducing titin phosphorylation in tandem with microvascular inflammation [12]. IL-6 also impairs natriuresis and triggers a series of pathological responses, such as oxidative stress, endothelial dysfunction and induction of myocyte apoptosis with adverse remodelling, which contributes to cardiomyocyte dysfunction and HF progression [13]. We propose that in the presented case, fluid retention and redistribution along with diastolic dysfunction triggered by the autoimmune/auto-inflammatory mechanism resulted in failure of the Fontan circulation. The major criteria for the diagnosis of ASIA syndrome include improvement of symptoms following removal of the inciting agent [1]. Although standard treatment of the syndrome does not exist, after the onset of ASIA symptoms, explantation of the allogenic material should be considered. According to a report by de Boer and colleagues, who reviewed the literature regarding symptoms after SBI explantation, 469 out of 622 (75%) patients experienced improvement of the silicone-related complaints after implant removal, while additional immunosuppressive treatment was necessary only when autoimmune disease developed [14]. During the past 5 years, several case series, including over 2000 patients, have been published regarding the effects of silicone explantation, reporting symptom improvement in 50–98% of the cases [1]. Several factors can influence the benefit of SBI explantation, such as implant, and disease characteristics, and the time duration between implantation and explantation [1]. An observational study showed more improvement in systemic symptoms in women who had their implants removed within 10 years, indicating that the duration of adjuvant exposure might be associated with the likelihood of improvement following adjuvant removal [15]. In conclusion, ASIA syndrome due to SBI can cause severe complications, including life-threatening circulatory failure. Removal of the implants can result in rapid clinical improvement. The duration of adjuvant exposure might be a crucial factor that determines symptom improvement following implant removal. In case of pre-existing cardiac conditions, potential complications associated with the implantation of aesthetic SBI should be carefully considered before such procedure is performed, and if symptoms develop after implantation, the option of implant removal should be raised without delay. Supplementary material is available at Rheumatology online. The data underlying this article will be shared on reasonable request to the corresponding author. A.I.N. is supported by the K-146732 OTKA grant of the Hungarian National Research Development and Innovation Office. Disclosure statement: The authors have declared no conflicts of interest. We would like to acknowledge Dr Szabina Pataki for the CT images. Patient consent: Written informed consent was obtained from the patient to publish her case.
No takes yet. Share an insight, caveat, or question.
Szappanos et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: